People need healthcare products and services regardless of what's happening with the economy. Which healthcare stocks could ...

Travere Therapeutics stock did suffer a bit of setback last week as the FDA moved back the anticipated decision date on a ...

Suzhou Sanegene Bio Inc. has gained clinical trial approval in China for SGB-3383 for the treatment of complement-mediated kidney diseases, including IgA nephropathy, C3 glomerulopathy, immune complex ...

Moderator Sagar Nigwekar, MD, of Massachusetts General Hospital in Boston, is joined by Edgar Lerma, MD, of the University of ...

Panelists discuss how disease-modifying therapies for immunoglobulin A (IgA) nephropathy, though initially more expensive ...

Panelists discuss how early diagnosis of immunoglobulin A (IgA) nephropathy enables timely interventions that can ...

Over a 35-year journey with a rare kidney disease, Ginger Murphy has become an advocate for her own health and welcomes the ...

Travere Therapeutics shares tumbled over 15% in extended trading Thursday after the company said the U.S. Food and Drug ...

From Kilkenny hurling to dialysis, his mindset remains strong, and now while on the transplant list for a kidney he is ...

Travere Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor ...